生物Nxt解决方案开发口服半类薄膜用于糖尿病和肥胖症. BioNxt Solutions develops oral semaglutide thin-film for diabetes and obesity.

生物Nxt解决方案正在开发一种用于糖尿病和肥胖的药物,即西马格卢提德 (semaglutide) 的口服薄膜输送系统. BioNxt Solutions is developing an oral thin-film delivery system for semaglutide, a drug used for diabetes and obesity. 该公司旨在为基于的治疗创建一个可扩展平台,并计划向其他GLP-1药物和其他疗法扩张. The company aims to create a scalable platform for peptide-based treatments, with plans to expand to other GLP-1 drugs and other therapies. 这一战略主要是提供无针,对患者友好的注射替代方案以改善药物坚持. This strategy focuses on offering needle-free, patient-friendly alternatives to injections to improve adherence.